BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd) ...
For local founder Rahmi Halaby, launching his company’s product to the public is the catalyst for its next phase of growth. Halaby’s company, Ideate, officially launched its first product — a platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback